Published online before print May 3, 2007, doi: 10.1161/01.RES.0000269182.22798.d9
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 American Heart Association, Inc.
Cellular Biology |
Generation of Functional Cardiomyocytes From Adult Mouse Spermatogonial Stem Cells
From the Departments of Cardiology and Pneumology (K.G., S.W., B.U., L.S.M., D.K., G.H.) and Pathology (B.H.) and the Institute of Human Genetics (K.N., W.E.), Georg-August-University of Göttingen, Germany
Correspondence to Prof Dr Gerd Hasenfuss, Department of Cardiology and Pneumology, Georg-August-University of Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany. E-mail hasenfus{at}med.uni-goettingen.de
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Stem cell–based therapy is a promising approach for the treatment of heart failure. Adult stem cells with the pluripotency of embryonic stem cells (ESCs) would be an ideal cell source. Recently, we reported the successful establishment of multipotent adult germline stem cells (maGSCs) from mouse testis. These cultured maGSCs show phenotypic characteristics similar to ESCs and can spontaneously differentiate into cells from all 3 germ layers. In the present study, we used the hanging drop method to differentiate maGSCs into cardiomyocytes and analyzed their functional properties. Differentiation efficiency of beating cardiomyocytes from maGSCs was similar to that from ESCs. The maGSC-derived cardiomyocytes expressed cardiac-specific L-type Ca2+ channels and responded to Ca2+ channel–modulating drugs. Cx43 was expressed at cell-to-cell contacts in cardiac clusters, and fluorescence recovery after photobleaching assay showed the presence of functional gap junctions among cardiomyocytes. Action potential analyses demonstrated the presence of pacemaker-, ventricle-, atrial-, and Purkinje-like cardiomyocytes. Stimulation with isoproterenol resulted in a significant increase in beating frequency, whereas the addition of cadmium chloride abolished spontaneous electrical activity. Confocal microscopy analysis of intracellular Ca2+ in maGSC-derived cardiomyocytes showed that calcium increased periodically throughout the cell in a homogenous fashion, pointing to a fine regulated Ca2+ release from intracellular Ca2+ stores. By using line-scan mode, we found rhythmic Ca2+ transients. Furthermore, we transplanted maGSCs into normal hearts of mice and found that maGSCs were able to proliferate and differentiate. No tumor formation was found up to 1 month after cell transplantation. Taken together, we believe that maGSCs provide a new source of distinct types of cardiomyocytes for basic research and potential therapeutic application.
Key Words: spermatogonial stem cells • cardiac differentiation • gap junction • L-type Ca2+ channels • cell transplantation
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
When heart muscle is damaged with myocyte apoptosis or necrosis, functional contracting cardiomyocytes are replaced by nonfunctional scar tissue. Experimental evidence suggests that the heart harbors a resident population of stem cells able to differentiate into cardiomyocytes, smooth muscle cells, and endothelial cells.1,2 A subset of native cardiac progenitors has been identified in hearts of newborn mice, rats, and humans.3 Despite the possible existence of these populations and their ability to contribute to cardiac repair, these intrinsic mechanisms are inadequate to restore the cardiac function of a failing heart. Therefore, a potential therapeutic approach for treatment of heart failure is to replace lost cardiomyocytes with new functional ones as an alternative to whole-heart transplantation.
Several groups have shown that functional cardiomyocytes can be differentiated from embryonic stem cells (ESCs), derived from the inner cell mass of preimplantation embryos.4 ESC-derived cardiomyocytes have been characterized by their developmentally controlled expression of cardiac-specific genes, proteins, and ion channels.5–8 Excitation–contraction coupling and electrophysiologic specialization also have been observed.9,10 Application of ESCs or ESC-derived cardiomyocytes for treatment of heart failure has already been tested in animal models and has demonstrated beneficial effects.11–14 However, to prevent the rejection of the implant, it is necessary to make the cells immunocompatible with the recipient. In addition, the use of human ESCs has encountered opposition that has led to considerations regarding limited availability.
To circumvent these problems, adult stem cells are under investigation. Transdifferentiation of adult stem cells in vivo into cardiomyocytes has been shown by some investigators15–17 but not by others.18,19 Moreover, only a few experiments have suggested that adult stem cells could generate cardiomyocytes under in vitro conditions.20,21 However, this has also been challenged by other studies.22
We recently showed that stem cells from adult mouse testis, similar to ESCs, are pluripotent.23 Spermatogonial stem cells (SSCs), a unique population of germline stem cells in adult testis, have the capability to self-renew and to produce daughter cells destined to differentiate into spermatozoa throughout life.24 We have successfully isolated SSCs from adult testis and established in vitro culture conditions to convert SSCs into ESC-like cells, the so called multipotent adult germline stem cells (maGSCs). These maGSCs show phenotypic characteristics similar to mouse ESCs. They can spontaneously differentiate into derivatives of all three germ layers in vitro. These data suggest that SSCs could be a new and promising source of adult stem cells for myocardial regeneration.
The purpose of the present study was to analyze the complex functional properties of cardiomyocytes derived from maGSCs in vitro and to analyze the behavior of undifferentiated maGSCs in normal hearts of mice in vivo after transplantation. Using molecular, cellular, and physiological assays, we found that maGSC-derived cardiomyocytes had similar properties to those derived from ESCs. They exhibited characteristics typical of heart cells in early stages of cardiac development. After transplantation of undifferentiated maGSCs into normal mouse hearts, they were able to proliferate and differentiate into vascular endothelial and smooth muscle cells in vivo, and no tumor formation was found up to 1 month after cell delivery.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In Vitro Differentiation of maGSCs
Established maGSC cultures (SSC5, C57BL6 line 9, FVB line 5, and 129 line 2) from different mouse strains were cultivated on a feeder layer of mouse embryonic fibroblasts in DMEM (Invitrogen) supplemented by 15% FCS (Invitrogen), L-glutamine (Invitrogen, 2 mmol/L), ß-mercaptoethanol (Serva, 50 µmol/L), nonessential amino acids (Invitrogen, stock solution diluted 1:100), and 103 units/mL recombinant human leukemia inhibitory factor (Chemicon) (ie, standard ESC culture conditions) as previously described.23 Standard ESC culture conditions were used for cultivation of mouse MPI-II ESCs.
For differentiation of maGSCs, the hanging drop method described for mouse ESC differentiation25 was applied for the formation of embryoid bodies (EBs). See the expanded Materials and Methods section in the online data supplement, at http://circres.ahajournals.org, for details on EB differentiation protocols, in vitro response of beating EBs to pharmacological agents, isolation of cardiomyocytes, immunocytochemistry, fluorescence recovery after photobleaching assay, action potential (AP) measurements, intracellular calcium measurements using confocal laser microscopy, and RT-PCR analysis.
Transplantation of maGSCs
The present study used female C57BL/6 mice obtained from the animal facility of the University of Göttingen. The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the NIH (NIH Publication No. 85-23, revised 1996) and was approved by the local government authority. Mouse maGSCs (line SSC5) labeled with a fluorescent carbocyanine dye CM-DiI (chloromethyl–1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine) (Invitrogen) were injected in the anterolateral wall of the heart or in the jugular vein. Hearts at 2 days and 1 and 4 weeks postinjection were analyzed by histochemical and immunohistological staining. Detailed information is available in the expanded Materials and Methods section in the online data supplement.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Induction of Cardiac Differentiation
Our initial studies show that maGSC lines (SSC5, SSC6, and SSC10) derived from double transgenic mice (Stra8-EGFP/Rosa26) can spontaneously differentiate into contracting cardiac clusters.23 Here we report that maGSCs derived from wild-type mice of 3 different strains (C57BL6, FVB, and 129/Ola) can also spontaneously differentiate into cardiomyocytes by inducing EB formation (Figure 1A through 1C). Spontaneously and rhythmically contracting cells appeared as clusters and were identified in approximately 40% of individual EBs (n=144; 3 independent experiments) derived from C57BL6 line 9 at day 5+2 (ie, 2 days after plating of 5-day-old EBs), increased to as many as 80% of the EBs by day 5+8, and declined to 50% by day 5+17 (Figure 1C). The size of beating cardiac clusters was
5% to 20% of EB outgrowths by day 5+8. The percentages of beating EBs derived from C57BL6 line 9 during differentiation was similar to those derived from line SSC5 and ESCs (Figure 1C). Similar results were seen in FVB line 5 (Figure 1C). However, lower differentiation efficiency was seen in 129/Ola line 2 in comparison with line SSC5 and ESCs (Figure 1C). The remainder of the experiments then focused on EBs or cardiomyocytes derived from C57BL6 line 9 and SSC5. RT-PCR assays showed that cardiomyocytes derived from C57BL6 line 9, similar to those derived from SSC5,23 expressed cardiac gene products in a developmentally controlled manner (data not shown).
|
Functional L-type Calcium Channels of maGSC-Derived Cardiomyocytes
In cardiac muscle, where Ca2+ influx across the sarcolemma is essential for contraction, the dihydropyridine-sensitive L-type calcium channel represents the major entry pathway of extracellular Ca2+.26 Using immunofluorescence staining with a specific antibody, we could show that the 
1 subunit of L-type calcium channels was expressed in cardiomyocytes at day 5+6 in a striated pattern (Figure 1D through 1F). The function of L-type calcium channels was examined in beating cardiac clusters at day 5+15 by evaluating chronotropic effects of cardioactive drugs. The L-type calcium channel activator (S)-BayK 8644 (1,4 dihydropyridine-type) showed dose-dependent positive chronotropic effects on the beating frequency of maGSC-derived cardiomyocytes, whereas the L-type calcium channel blocker diltiazem (1,5-benzothiazepine-type) showed dose-dependent negative chronotropic effects (Figure 1G). Treatment with 10–5 mol/L (S)-BayK 8644 doubled the beating frequency. Treatment with 10–5 mol/L diltiazem almost completely blocked the contractions. Contractions recovered to a normal frequency 24 hours after removal of the drug. These results indicate that functional L-type calcium channels exist in the maGSC-derived cardiomyocytes.
Functional Cell-to-Cell Communication
To analyze the cell-to-cell coupling in the synchronously contracting cardiac clusters, we performed double-staining using antibodies against either pan-cadherin and -actinin or connexin 43 (Cx43) and cardiac troponin T. We found that pan-cadherin localized at cell–cell junctions, indicating the presence of adhering junctions between cardiomyocytes (Figure 2A through 2C). In addition, Cx43 staining indicated the presence of gap junctions between cells in cardiac clusters (Figure 2D through 2F). Functional coupling between cells was confirmed by fluorescence recovery after photobleaching analysis. Fluorescence recovery of a gap junction–permeable dye (calcein–acetoxy methyl ester [AM]) was observed consistently for cardiomyocytes within 5 minutes after photobleaching (Figure 3A). When cells were exposed to carbenoxolone (50 µmol/L), a gap junction uncoupler, the fluorescence recovery was disrupted (Figure 3B). Fluorescence in cardiomyocytes recovered to 25.6±5.6% (n=15) after 30 seconds and carbenoxolone significantly blocked the percentage of refill to 4.3±2.4% (n=9; P<0.05) (Figure 3C). The magnitude of functional gap junctions (or the gap junction permeability) was assessed by the rate of fluorescence recovery (k), which reflected the diffusion of calcein-AM from unbleached neighbors into a laser-bleached cell. The recovery rate in maGSC-derived cardiomyocytes was 0.47±0.06 min–1 (n=15), and the application of carbenoxolone resulted in a significantly lower rate of recovery (k=0.04±0.04 min–1; n=7; P<0.05; Figure 3D). These observations suggest that gap junctions function as a conduit of intercellular communication between cardiomyocytes and play an important role in cell-to-cell communication, essential for the synchronization of myocardial contractile activity and intact electromechanical coupling.
|
|
Action Potential Characteristics
In mature cardiac cells, depolarization of the cell membrane during the AP activates L-type Ca2+ channels, leading to Ca2+ influx and subsequent release of Ca2+ from intracellular calcium stores. To characterize whether mouse maGSC-derived cardiomyocytes could enter a fully differentiated cardiac phenotype, the dissociated cardiomyocytes were analyzed by patch–clamp. Mouse maGSC-derived cardiomyocytes showed spontaneous APs (Figure 4A). We examined the shape and properties of APs from 68 single beating cardiomyocytes. Four major types of APs characteristic for pacemaker- (n=8), ventricle- (n=23), atrial- (n=9), and Purkinje-like (n=9) cells were found (Figure 4A) with distinct morphologies at day 5+9. This classification was based on the shapes (Figure 4A) and the properties of the AP as measured by upstroke velocity (dV/dtmax), AP amplitude (APA), AP duration at 90% and 80% of repolarization, and maximum diastolic potential as summarized in the supplemental Table I. Pacemaker-like APs are characterized by prominence of phase 4 depolarization, slow dV/dtmax, and a smaller APA. The ventricle-like APs can be distinguished by the presence of a significant plateau phase of the AP, resulting in a long duration, and high dV/dtmax and APA. The atrial-like APs show a triangular shape with a short duration and high dV/dtmax and APA. The Purkinje-like APs are characterized by the presence of a notch and plateau-phase and high dV/dtmax. In addition, a subset of cells (n=19) showed an intermediate AP phenotype (Figure 4B), which exhibited characteristics of both ventricle- and pacemaker-like morphology (slow dV/dtmax, long duration; supplemental Table I).
|
To determine the functional expression of ß-adrenergic receptors in cardiomyocytes, we studied the effects of ß-adrenergic agonist isoproterenol (1 µmol/L) on APs. The isoproterenol stimulation resulted in the significant increase of AP frequency from 0.80±0.15 to 1.62±0.21 Hz (n=5; P<0.05; Figure 4C), demonstrating that ß-adrenergic receptors are present in maGSC-derived cardiomyocytes and stimulation of these receptors produces a positive chronotropic response. Furthermore, cadmium (0.5 mmol/L), a nonspecific blocker of voltage-gated Na+ and L-type Ca2+ channels, completely abolished spontaneous APs (Figure 4D), proving that Na+ and Ca2+ channels critically contribute to the observed APs. A further hint for the involvement of fast depolarizing Na+ channels are AP upstroke velocities in the magnitude of 30 to 50 V/s–1 for ventricle-, Purkinje-, and atrial-like APs (supplemental Table I). In particular, ventricle- and Purkinje-like APs showed plateau phases obviously caused by Ca2+ channel currents.
Ca2+ Transients and Ca2+ Sparks
We assessed the spontaneous intracellular Ca2+ fluctuations in maGSC-derived cardiomyocytes using confocal microscopy. A typical triangle-shaped cardiomyocyte during low-diastolic [Ca2+]i and high-systolic [Ca2+]i is presented in Figure 5A. Calcium increased homogenously throughout the cell, pointing to a fine-regulated Ca2+ release from intracellular Ca2+ stores, most likely the sarcoplasmic reticulum (SR) (supplemental Figure I; supplemental Video 1). The amplitudes of Ca2+ transient measured in maGSC-derived cardiomyocytes were 464±77 nmol/L (filled bar; n=15) versus 287±69 nmol/L measured in ESC-derived cardiomyocytes (open bar; n=5; statistically not significant; Figure 5B). Both are in the range of amplitudes measured in adult cardiomyocytes.27 Using line-scan mode, rhythmic Ca2+ transients were found (Figure 5C) and even small elementary Ca2+ release events (Ca2+ sparks28; Figure 5D), which are mainly attributable to SR Ca2+ release through a cluster of ryanodine receptors (RyRs), appeared. Ca2+ sparks were previously described in increasing numbers at later stages of cardiomyocytes derived from ESCs.29
|
The cardiac RyR2 serves as the major SR calcium-release channel to mediate the rapid rise of cytosolic free calcium. We found that the gene encoding RyR2 was expressed during EB differentiation (Figure 6A). In addition, genes encoding phospholamban, SERCA2a, and Na+/Ca2+ exchanger (NCX)1, as well as calsequestrin, a high-capacity Ca2+-binding protein in the SR, were expressed (Figure 6A). This expression pattern was similar to those described for cardiac differentiation of ESCs.5 To study the distribution of RyR2 and the Ca2+-handling proteins SERCA2a and NCX1 throughout cardiomyocytes, we performed double staining in maGSC-derived cardiomyocytes at day 5+18. We found mainly a diffuse distribution of RyR2 in maGSC-derived cardiomyocytes (Figure 6B). Of note, we observed partial organization of RyR2 in striated-like structures (Figure 6B, arrow), which are not found in cardiomyocytes until postnatal day 6 when SR begins to organize.30 Immunocytochemical staining revealed that SERCA2a and NCX1 were mainly expressed in a fine granular, network-like pattern throughout cardiomyocytes (Figure 6C and 6D) comparable to those of neonatal cardiomyocytes.30,31 These results suggest that the organization of the SR is not fully developed in maGSC-derived cardiomyocytes.
|
Effect of Cardiac Environment on Development of maGSCs In Vivo
We further tested the effect of cardiac environment on the development of maGSCs in vivo. CM-DiI–labeled maGSCs (0.5 to 1x106) were injected into the left ventricular free wall of female C57BL/6 mice. Given that the transplanted cells were DiI-labeled, whereas the myocardium of the recipient mice was not, the fate of donor cells was readily monitored by fluorescence microscopic examination. Two days after cell application, DiI-labeled cells could be found again in mice (n=5; Figure 7A). Hematoxylin/eosin (H&E) staining showed that these cells in small clusters were stained in blue (Figure 7D). One week after cell application, DiI-labeled cells could be found again in the recipients (n=4; Figure 7B). This data were confirmed by H&E staining of heart sections revealing that one week post-injection of cells, left ventricular regions of mice frequently contained larger clusters of cells with large nuclei which were stained dark blue (Figure 7E). One month after cell injection, DiI-labeled cells could still be found in heart sections of mice (n=6; Figure 7C). However, they no longer contained large nuclei and were not stained dark blue (Figure 7F). Furthermore, none of the transplanted hearts showed evidence of tumor or teratoma formation on histological evaluation.
|
In addition, we tested whether cells could migrate into hearts after intravenous cell delivery. We found that only very a few single cells could be detected at 2 days after application (data not shown).
The fate of donor cells following intramyocardial injection was determined using immunohistochemical assays. In transplanted hearts at 1 week after cell injection, immunolabeling with an antibody specific for Oct4, a germline-specific transcription factor often used to characterize pluripotent stem cells, revealed large aggregates of labeled cells in the myocardium (Figure 8A). In a parallel section, the Oct4-positive cell aggregates were also stained dark blue by H&E staining (date not shown), suggesting the presence of undifferentiated and nonmature cells in the left ventricles of recipients. As shown in Figure 7E, there were cells with elongated nuclei adjacent to the dark blue–stained cells. They were Oct4 negative (Figure 8A), suggesting that these cells lost their pluripotency. However, when the sections were stained with an antibody against the cell proliferation marker Ki-67, we found that some cells with elongated nuclei were positive for Ki-67 (Figure 8C), indicating that they still have the proliferation potential. One month after cell transplantation, no Oct4- or Ki-67–positive cells were found (Figure 8B and 8D). Immunolabeling for cardiac troponin T showed that none of the transplanted cells expressed cardiac troponin T at either 1 week (supplemental Figure IIA through IIC) or 1 month (supplemental Figure IID through IIF). When the sections at 1 month were stained with antibodies against von Willebrand factor (vWF) and smooth muscle--actin (SM--actin), we found that some of labeled cells were positive for vWF (Figure 8E through 8G) and SM--actin (Figure 8H and 8I), indicating that the transplanted maGSCs could differentiate into vascular endothelial and smooth muscle cells. In addition, Masson–Goldner trichrome staining showed that fibrosis (light blue staining) developed in the heart at 1 week (Figure 7H) and 1 month (Figure 7I) postinjection of cells, whereas almost no fibrosis was visible in the transplants at 2 days (Figure 7G).
|
Taken together, these findings demonstrate that transplanted maGSCs are able to proliferate and differentiate in the normal heart. Some cells lost their pluripotency but still were proliferating 1 week after cell delivery. After 1 month, no proliferating cells were observed, and until this time, no tumor or teratomas were formed. Although transplanted maGSCs can differentiate into vascular endothelial and smooth muscle cells, no mature cardiomyocytes developed.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We report here that cardiomyocytes can be generated from multiple mouse maGSC lines with an efficiency comparable to cardiac differentiation of mouse ESCs. The cardiomyocytes derived from maGSCs express L-type calcium channels and respond to cardioactive drugs. Functional gap junctions are present between cardiac cells. AP analysis demonstrates the presence of pacemaker-, ventricle-, atrial-, and Purkinje-like cardiomyocytes. The cardiomyocytes also exhibit the complex functional properties of native cardiomyocytes, including a positive or negative response to ß-adrenergic stimulation or Ca2+ blockers and an intact calcium cycling. After intramyocardial injection, maGSCs are able to proliferate and differentiation without tumor formation.
The use of a cell therapy approach to replace lost cardiomyocytes with new cardiomyocytes that could be grafted would represent an invaluable technique for the treatment of heart failure. Such an application has already been demonstrated in animal models using ESCs as well as other adult stem cells. However, some studies have indicated that the capacity of transdifferentiation of other adult stem cells into cardiomyocytes may be limited18,19 or that fusion of stem cells with cardiomyocytes may occur.32,33 In contrast, ESCs have been proven to be pluripotent.4 However, the use of human ESCs has encountered opposition that has led to considerations regarding limited availability. Therefore, adult stem cells with the pluripotency of ESCs would be ideal for cell-based regeneration strategies.
Our results show that mouse maGSCs, derived from SSCs in culture, are similar to ESCs. When maGSCs were cultivated as EBs in hanging drops, as described for mouse ESCs, they spontaneously differentiated into functional cardiomyocytes with an efficiency similar to that seen with ESCs. Spontaneously beating cardiomyocytes could be derived from approximately 80% of EBs. Beating frequency could be modulated by isoproterenol, indicating functional ß-adrenergic receptors. AP measurements showed 4 major types of APs that were characteristic of specialized cardiomyocytes from sinus node, ventricle, atrium, and Purkinje fibers, and similar to those found in ESC-derived cardiomyocytes.5–7,9
Excitation–contraction coupling systems of maGSC-derived cardiomyocytes showed all major components and resembled those of neonatal cardiomyocytes regarding the degree of maturation. This included L-type calcium channels sensitive to the calcium channel activator (S)-BayK8644 and the calcium channel blocker diltiazem, as well as calcium binding and cycling proteins, such as RyR, calsequestrin, sarcoplasmic reticulum calcium pump, phospholamban, and sarcolemmal sodium calcium exchanger.
We also observed organization of RyRs in a striated-like structure in maGSC-derived cardiomyocytes, similar to those in postnatal cardiomyocytes.30 Development of SR and functional excitation–contraction coupling is obvious from the presence of Ca2+ sparks and Ca2+ transients in maGSC-derived cardiomyocytes. Critically important for cardiac function, we show that maGSCs derived cardiomyocytes express the gap junction protein Cx43 and develop cell-to-cell coupling. Again, cardiomyocytes derived from maGSCs were structurally and functionally comparable to those obtained from ESCs.
The finding that transplanted maGSCs are able to proliferate in the heart is consistent with the known self-renewal property of the cell source. We observed that maGSCs transplanted into normal hearts lost their proliferating potential at 1 month and differentiated into vascular endothelial and smooth muscle cells but did not differentiate into cardiomyocytes. When maGSCs were cultured as EBs, which resemble early postimplantation embryos, they were able to spontaneously differentiate into functional cardiomyocytes in vitro at day 5+8.23 However, they could not spontaneously differentiate into cardiomyocytes in the normal heart at 1 month postinjection of cells. It is possible that cardiac differentiation may occur at later time points that have not been investigated yet. Alternatively, local microenvironment might be a critical determinate of the fate of the transplanted maGSCs. This is also in line with previous studies showing that in the absence of myocardial infarction, only rare transplanted ESCs remained in the heart at 2 weeks.34 However, undifferentiated mouse ESCs transplanted directly into the infarcted heart could differentiate into cardiomyocytes and vascular smooth muscle and endothelial cells.11,12,34,35 It will be interesting to investigate whether maGSCs or predifferentiated maGSCs can contribute to the cardiac and vascular lineages in the absence of fusion after cellular transplantation into the infarcted heart.
Although maGSCs proliferated after transplantation, under the present conditions, no teratoma/tumor formation was observed, despite the known ability of these cells to form teratomas under certain conditions. This seems consistent with earlier studies transplanting mouse ESCs into rat or mouse hearts.11,34,35 However, this is in contrast to a recent study showing that undifferentiated ESCs formed teratomas in both normal and infarcted hearts of nude or immunocompetent syngeneic mice. Even allogenic ESCs caused teratomas, but these were immunologically rejected after several weeks.36 Of course, we cannot exclude that maGSCs may form teratomas with experimental conditions different from those used in the present study. However, absence of teratoma formation may also suggest that our maGSCs are different from mouse ESCs in this regard.
The present findings open new possibilities for basic research on cardiac development as well as cardiac regeneration. SSCs can be easily derived from transgenic animals to study the effects of genetic manipulation on myocyte development and maturation. Moreover, these functional cardiomyocytes may be able to engraft into the damaged host myocardium and function as cardiomyocytes after transplantation. Most importantly, if the present technique could be transferred to human tissue, this would open new options for human cardiac regeneration without the ethical problem associated with ESCs. SSCs and maGSCs could be obtained from testicular biopsies without the use of human embryonic tissue. Moreover, the availability of immunocompatible tissue for autotransplantation would circumvent immunological problems associated with ESC-based therapy. Finally, we postulate that regeneration strategies using maGSCs may be based on techniques that have been developed previously for ESCs.
In conclusion, we have demonstrated that functional cardiomyocytes can be derived from adult stem cells. These maGSC-derived cardiomyocytes can now be tested for their ability to restore the function of damaged hearts in animal models. A major challenge will be to produce functional cardiomyocytes derived from human SSCs and to use them in cell-based therapies for heart disease.
|
Acknowledgments |
|---|
We thank Anke Cierpka and Yvonne Hintz for excellent technical assistance.
Sources of Funding
This work was supported by a Heidenreich von Siebold-Program 2006 grant from the Georg-August-University of Göttingen (to K.G.), the Deutsche Forschungsgemeinschaft Klinische Forschergruppe (K.G., L.S.M., K.N., W.E., and G.H), Deutsche Forschungsgemeinschaft Emmy-Noether-Program grant MA1982/1-5 (to L.S.M.), and Bundesministerium für Bildung und Forschung grant G3-11 (to G.H.).
Disclosures
None.
|
Footnotes |
|---|
*These authors contributed equally to this work.
Original received July 4, 2006; resubmission received February 21, 2007; revised resubmission received March 30, 2007; accepted April 25, 2007.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114: 763–776.[CrossRef][Medline] [Order article via Infotrieve]
2. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, Pocius J, Michael LH, Behringer RR, Garry DJ, Entman ML, Schneider MD. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003; 100: 12313–12318.
3. Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodard S, Lin LZ, Cai CL, Lu MM, Reth M, Platoshyn O, Yuan JX, Evans S, Chien KR. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005; 433: 647–653.[CrossRef][Medline] [Order article via Infotrieve]
4. Wobus AM, Boheler KR. Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev. 2005; 85: 635–678.
5. Boheler KR, Czyz J, Tweedie D, Yang HT, Anisimov SV, Wobus AM. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circ Res. 2002; 91: 189–201.
6. Wobus AM, Rohwedel J, Maltsev V, Hescheler J. Development of cardiomyocytes expressing cardiac-specific genes, action potentials, and ionic channels during embryonic stem cell-derived cardiogenesis. Ann N Y Acad Sci. 1995; 752: 460–469.[Medline] [Order article via Infotrieve]
7. Hescheler J, Fleischmann BK, Lentini S, Maltsev VA, Rohwedel J, Wobus AM, Addicks K. Embryonic stem cells: a model to study structural and functional properties in cardiomyogenesis. Cardiovasc Res. 1997; 36: 149–162.
8. Guan K, Furst DO, Wobus AM. Modulation of sarcomere organization during embryonic stem cell-derived cardiomyocyte differentiation. Eur J Cell Biol. 1999; 78: 813–823.[Medline] [Order article via Infotrieve]
9. Maltsev VA, Rohwedel J, Hescheler J, Wobus AM. Embryonic stem cells differentiate in vitro into cardiomyocytes representing sinusnodal, atrial and ventricular cell types. Mech Dev. 1993; 44: 41–50.[CrossRef][Medline] [Order article via Infotrieve]
10. He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res. 2003; 93: 32–39.
11. Hodgson DM, Behfar A, Zingman LV, Kane GC, Perez-Terzic C, Alekseev AE, Puceat M, Terzic A. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol. 2004; 287: H471–H479.
12. Behfar A, Zingman LV, Hodgson DM, Rauzier JM, Kane GC, Terzic A, Puceat M. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J. 2002; 16: 1558–1566.
13. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J Clin Invest. 1996; 98: 216–224.[Medline] [Order article via Infotrieve]
14. Menard C, Hagege AA, Agbulut O, Barro M, Morichetti MC, Brasselet C, Bel A, Messas E, Bissery A, Bruneval P, Desnos M, Puceat M, Menasche P. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet. 2005; 366: 1005–1012.[CrossRef][Medline] [Order article via Infotrieve]
15. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001; 98: 10344–10349.
16. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001; 410: 701–705.[CrossRef][Medline] [Order article via Infotrieve]
17. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodell MA. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest. 2001; 107: 1395–1402.[CrossRef][Medline] [Order article via Infotrieve]
18. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004; 428: 668–673.[CrossRef][Medline] [Order article via Infotrieve]
19. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004; 428: 664–668.[CrossRef][Medline] [Order article via Infotrieve]
20. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999; 103: 697–705.[Medline] [Order article via Infotrieve]
21. Badorff C, Brandes RP, Popp R, Rupp S, Urbich C, Aicher A, Fleming I, Busse R, Zeiher AM, Dimmeler S. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation. 2003; 107: 1024–1032.
22. Gruh I, Beilner J, Blomer U, Schmiedl A, Schmidt-Richter I, Kruse ML, Haverich A, Martin U. No evidence of transdifferentiation of human endothelial progenitor cells into cardiomyocytes after coculture with neonatal rat cardiomyocytes. Circulation. 2006; 113: 1326–1334.
23. Guan K, Nayernia K, Maier LS, Wagner S, Dressel R, Lee JH, Nolte J, Wolf F, Li M, Engel W, Hasenfuss G. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature. 2006; 440: 1199–1203.[CrossRef][Medline] [Order article via Infotrieve]
24. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature. 2001; 414: 98–104.[CrossRef][Medline] [Order article via Infotrieve]
25. Wobus AM, Guan K, Yang HT, Boheler KR. Embryonic stem cells as a model to study cardiac, skeletal muscle, and vascular smooth muscle cell differentiation. Methods Mol Biol. 2002; 185: 127–156.[Medline] [Order article via Infotrieve]
26. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002; 415: 198–205.[CrossRef][Medline] [Order article via Infotrieve]
27. Maier LS, Zhang T, Chen L, DeSantiago J, Brown JH, Bers DM. Transgenic CaMKIIdeltaC overexpression uniquely alters cardiac myocyte Ca2+ handling: reduced SR Ca2+ load and activated SR Ca2+ release. Circ Res. 2003; 92: 904–911.
28. Cheng H, Lederer WJ, Cannell MB. Calcium sparks: elementary events underlying excitation-contraction coupling in heart muscle. Science. 1993; 262: 740–744.
29. Sauer H, Theben T, Hescheler J, Lindner M, Brandt MC, Wartenberg M. Characteristics of calcium sparks in cardiomyocytes derived from embryonic stem cells. Am J Physiol Heart Circ Physiol. 2001; 281: H411–H421.
30. Mohler PJ, Gramolini AO, Bennett V. The ankyrin-B C-terminal domain determines activity of ankyrin-B/G chimeras in rescue of abnormal inositol 1,4,5-trisphosphate and ryanodine receptor distribution in ankyrin-B (-/-) neonatal cardiomyocytes. J Biol Chem. 2002; 277: 10599–10607.
31. Most P, Boerries M, Eicher C, Schweda C, Volkers M, Wedel T, Sollner S, Katus HA, Remppis A, Aebi U, Koch WJ, Schoenenberger CA. Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. J Cell Sci. 2005; 118: 421–431.
32. Terada N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, Meyer EM, Morel L, Petersen BE, Scott EW. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature. 2002; 416: 542–545.[CrossRef][Medline] [Order article via Infotrieve]
33. Ying QL, Nichols J, Evans EP, Smith AG. Changing potency by spontaneous fusion. Nature. 2002; 416: 545–548.[CrossRef][Medline] [Order article via Infotrieve]
34. Singla DK, Hacker TA, Ma L, Douglas PS, Sullivan R, Lyons GE, Kamp TJ. Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types. J Mol Cell Cardiol. 2006; 40: 195–200.[CrossRef][Medline] [Order article via Infotrieve]
35. Min JY, Yang Y, Converso KL, Liu L, Huang Q, Morgan JP, Xiao YF. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. J Appl Physiol. 2002; 92: 288–296.
36. Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, Masino A, Muskheli V, Pabon L, Reinecke H, Murry CE. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 2007.
This article has been cited by other articles:
 |
|
 |
|
  J. S. Forrester, A. J. White, S. Matsushita, T. Chakravarty, and R. R. Makkar New Paradigms of Myocardial Regeneration Post-Infarction: Tissue Preservation, Cell Environment, and Pluripotent Cell Sources J. Am. Coll. Cardiol. Intv., January 1, 2009; 2(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jawad, A. R. Lyon, S. E. Harding, N. N. Ali, and A. R. Boccaccini Myocardial tissue engineering Br. Med. Bull., September 1, 2008; 87(1): 31 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mauritz, K. Schwanke, M. Reppel, S. Neef, K. Katsirntaki, L. S. Maier, F. Nguemo, S. Menke, M. Haustein, J. Hescheler, et al. Generation of Functional Murine Cardiac Myocytes From Induced Pluripotent Stem Cells Circulation, July 29, 2008; 118(5): 507 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. de Rooij and S. C. Mizrak Deriving multipotent stem cells from mouse spermatogonial stem cells: a new tool for developmental and clinical research Development, July 1, 2008; 135(13): 2207 - 2213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Smart and P. R. Riley The Stem Cell Movement Circ. Res., May 23, 2008; 102(10): 1155 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Orlandi, F. Pagani, D. Avitabile, G. Bonanno, G. Scambia, E. Vigna, F. Grassi, F. Eusebi, S. Fucile, M. Pesce, et al. Functional properties of cells obtained from human cord blood CD34+ stem cells and mouse cardiac myocytes in coculture Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1541 - H1549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Highlights From The Literature Physiology, October 1, 2007; 22(5): 299 - 302. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||